Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study

Aim and Objectives: Direct-acting antiviral (DAA) therapy can cure chronic hepatitis C (CHC), and daclatasvir (DCV)/asunaprevir (ASV) was the first interferon-free DAA therapy introduced in Korea. Patients who achieve sustained virologic response (SVR) after DAA treatment are expected to have good p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jae-Hyun, Kim, Sung-Eun, Cho, Su-Hyeon, Kim, Gi-Ae, Park, Yewan, Park, Ji-Won, Kang, Seong-Hee, Lee, Young-Sun, Kim, Jeong-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456703/
https://www.ncbi.nlm.nih.gov/pubmed/37629725
http://dx.doi.org/10.3390/medicina59081436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456703/
https://www.ncbi.nlm.nih.gov/pubmed/37629725
http://dx.doi.org/10.3390/medicina59081436

Ejemplares similares